Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility StudyLaetitia E. Lamberts, Gooitzen M. van Dam, Maximillian Koch et al.|Clinical Cancer Research|2016Cited by 289
Supplementary Figure 7 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility StudyLaetitia E. Lamberts, Gooitzen M. van Dam, Maximillian Koch et al.|Unknown|2023Cited by 0
Supplemental Material and Methods from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility StudyLaetitia E. Lamberts, Gooitzen M. van Dam, Maximillian Koch et al.|Unknown|2023Cited by 0
Supplementary Figure 2 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility StudyLaetitia E. Lamberts, Gooitzen M. van Dam, Willem P.Th.M. Mali et al.|Unknown|2023Cited by 0
Supplementary Figure 5 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility StudyLaetitia E. Lamberts, Gooitzen M. van Dam, Maximillian Koch et al.|Unknown|2023Cited by 0